Lunch and Learn session at ABI-LAB- Hosted by Biocytogen Boston Corp

27 Strathmore Road,Natick MA 01760

09 February, 2022

Description

Biocytogen is excited to invite you to attend a lunch and learn session partnering up with the ABI-Lab. High-throughput therapeutic antibody discovery using series of humanized mouse modelsJames Jin, Ph.D. Vice President of Biocytogen Antibody drug discovery is a long and complex process involving multiple technologies and platforms. The process involves significant risk, and many candidates fail to enter the clinic because of the lack of a high throughput developability workflow and effective methods for in vivo evaluation prior to clinical trials. Further adding to the complexity is the process of target selection for antibody drug development. In this session, we will discuss how Biocytogen’s state-of-the-art humanized mouse platforms and screening technologies synergize to accelerate and de-risk the entire process of antibody drug discovery and development, including: • Improved models to assist with drug target selection • Humanized antibody mice, including target-specific KO mice, to maximize coverage of novel targets and epitopes • Single B-cell antibody discovery technologies, including Beacon® technology, for improved high-throughput screening • Humanized target mice for in vivo efficacy evaluation • Advanced developability and engineering workflow James Jin, PhDVice President of Biocytogen Dr. James Jin received his PhD in Virology at Wuhan University in 1997. After completing postdoctoral training at Colorado State University, he worked as a Research Assistant Professor at the University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a Senior Scientist. Dr. Jin joined Biocytogen as the Director of Technology in 2011, where he was promoted to vice president. His research expertise spans the fields of virology, immunology, proteomics, protein structure, human stem cell, and genetic engineering.